



[www.MedChemExpress.com](http://www.MedChemExpress.com)











Inhibitors, Screening Libraries, Proteins

# nAChR

## Nicotinic acetylcholine receptors

nAChRs (nicotinic acetylcholine receptors) are neuron receptor proteins that signal for muscular contraction upon a chemical stimulus. They are cholinergic receptors that form ligand-gated ion channels in the plasma membranes of certain neurons and on the presynaptic and postsynaptic sides of the neuromuscular junction. Nicotinic acetylcholine receptors are the best-studied of the ionotropic receptors. Like the other type of acetylcholine receptor—the muscarinic acetylcholine receptor (mAChR)—the nAChR is triggered by the binding of the neurotransmitter acetylcholine (ACh). Just as muscarinic receptors are named such because they are also activated by muscarine, nicotinic receptors can be opened not only by acetylcholine but also by nicotine—hence the name "nicotinic".

## nAChR Agonists, Antagonists, Inhibitors, Activators & Modulators


<p><b>(+)-Sparteine</b></p> <p>Cat. No.: HY-W008350</p> <p>(+)-Sparteine is a natural alkaloid acting as a ganglionic blocking agent. (+)-Sparteine competitively blocks <b>nicotinic ACh receptor</b> in the neurons.</p> <p><b>Purity:</b> ≥97.0%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM × 1 mL, 100 mg</p> 	<p><b>(+)-Sparteine sulfate pentahydrate</b>  <b>(+)-Lupinidine sulfate pentahydrate</b></p> <p>Cat. No.: HY-B1304A</p> <p>(+)-sparteine (sulfate pentahydrate) is a ganglionic blocking agent. (+)-Sparteine competitively blocks <b>nicotinic ACh receptor</b> in the neurons.</p> <p><b>Purity:</b> ≥98.0%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 50 mg</p> 
<p><b>(-)-(S)-B-973B</b></p> <p>Cat. No.: HY-114269</p> <p>(-)-(S)-B-973B is a potent allosteric agonist and positive allosteric modulator of <b>α7 nAChR</b>, with antinociceptive activity.</p> <p><b>Purity:</b> 99.93%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p><b>(R)-(+)-Anatabine</b></p> <p>Cat. No.: HY-126047B</p> <p>(R)-(+)-Anatabine is a less active R-enantiomer of Anatabine. Anatabine is a potent <b>α4β2 nAChR</b> agonist. Anatabine inhibits <b>NF-κB</b> activation lower <b>amyloid-β (Aβ)</b> production by preventing the β-cleavage of amyloid precursor protein (APP).</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 
<p><b>(R)-Dinotefuran</b>  <b>((R)-MTI-446)</b></p> <p>Cat. No.: HY-B0827A</p> <p>(R)-Dinotefuran ((R)-MTI-446), a neonicotinoid pesticide, exhibits comparative insecticidal activities (1.7-2.4 times) to typical sucking pests <i>Aphis gossypii</i> and <i>Apolygus lucorum</i> compared to racemic mixtures by inhibiting <b>nicotinic acetylcholine receptors</b>.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 	<p><b>(Rac)-ABT-202 dihydrochloride</b></p> <p>Cat. No.: HY-124540B</p> <p>(Rac)-ABT-202 dihydrochloride is a racemate of ABT-202. ABT-202 is an agonist of nicotinic acetylcholine receptors (nAChRs) and can be used as an analgesic.</p> <p><b>Purity:</b> ≥95.0%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 50 mg</p> 
<p><b>(Rac)-CP-601927 hydrochloride</b></p> <p>Cat. No.: HY-138879A</p> <p>(Rac)-CP-601927 hydrochloride is the racemate of CP-601927. CP-601927 is a nAChR agonist with <math>K_i</math> values 1.2 nM and 102 nM for <b>α4β2</b> and <b>α3β4</b> nAChR, respectively.</p> <p><b>Purity:</b> 99.95%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p><b>(Rac)-Monepantel sulfone-d5</b></p> <p>Cat. No.: HY-14774S1</p> <p>(Rac)-Monepantel sulfone-d5 is deuterium labeled Monepantel. Monepantel is organic anthelmintic, and acts as a positive allosteric modulator of a nematode-specific clade of nicotinic acetylcholine receptor (nAChR) subunits.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 
<p><b>(Rac)-Monepantel-d5</b></p> <p>Cat. No.: HY-14774S</p> <p>(Rac)-Monepantel-d5 is deuterium labeled Monepantel. Monepantel is organic anthelmintic, and acts as a positive allosteric modulator of a nematode-specific clade of nicotinic acetylcholine receptor (nAChR) subunits.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 	<p><b>(rel)-Asperparaline A</b>  <b>((rel)-Aspergillimide; (rel)-VM55598)</b></p> <p>Cat. No.: HY-124874</p> <p>(rel)-Asperparaline A ((rel)-Aspergillimide), an anthelmintic metabolite, is isolated from okara that has been fermented with <i>Aspergillus japonicus</i> JV-23. (rel)-Asperparaline A is also a potent and selective antagonist of <b>nAChR</b>.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 5 mg</p> <p>Rotation (-)</p> 

### (S)-(-)-Levamisole

(Levamisole; L-Tetramisole; Levamisol)

Cat. No.: HY-A0106

(S)-(-)-Levamisole (Levamisole), an anthelmintic agent with immunomodulatory properties. (S)-(-)-Levamisole acts as a positive allosteric modulator (PAM) for the  $\alpha 3\beta 2$  ( $EC_{50}=300 \mu\text{M}$ ) and  $\alpha 3\beta 4$  ( $EC_{50}=100 \mu\text{M}$ ) subtype of nAChRs. Orally active.




**Purity:** >98%  
**Clinical Data:** Launched  
**Size:** 100 mg

### (S)-Dinotefuran

(S)-MTI-446)

Cat. No.: HY-B0827B

(S)-Dinotefuran ((S)-MTI-446), a neonicotinoid pesticide, is toxic by binding to  $\alpha 8$  subunit of nAChR of honeybee *Apis mellifera* (*Apis mellifera* Linnaeus). (S)-Dinotefuran shows more toxic than R-dinotefuran to honeybee *Apis mellifera*.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### (S)-UFR2709

Cat. No.: HY-137231A

(S)-UFR2709 is a competitive nAChR antagonist and displays higher affinity for  $\alpha_4\beta_2$  nAChRs than for  $\alpha_7$  nAChRs. (S)-UFR2709 decreases anxiety and reduces ethanol consumption and ethanol preference in alcohol-preferring rats.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### (S)-UFR2709 hydrochloride

Cat. No.: HY-137231B

(S)-UFR2709 (hydrochloride) is a competitive nAChR antagonist and displays higher affinity for  $\alpha_4\beta_2$  nAChRs than for  $\alpha_7$  nAChRs. (S)-UFR2709 (hydrochloride) decreases anxiety and reduces ethanol consumption and ethanol preference in alcohol-preferring rats.




**Purity:** 98.08%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM  $\times$  1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

### ( $\pm$ )-Anatoxin A fumarate

Cat. No.: HY-N2326

( $\pm$ )-Anatoxin A fumarate is a natural alkaloid isolated from freshwater cyanobacterium.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### 3-Bromocytisine

(3-Br-cytisine)

Cat. No.: HY-107684

3-Bromocytisine (3-Br-cytisine) is a potent nAChR receptors agonist, with  $IC_{50}$ s are 0.28, 0.30 and 31.6 nM for  $\alpha 4\beta 4$ ,  $\alpha 4\beta 2$ , and  $\alpha 7$ -nACh, respectively.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### 4BP-TQS

Cat. No.: HY-110087

4BP-TQS is a potent allosteric agonist of  $\alpha 7$  nAChR. 4BP-TQS activates nAChRs via an allosteric transmembrane site.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### 5-AAM-2-CP

Cat. No.: HY-136608

5-AAM-2-CP is a major metabolite of Acetamidrid. Acetamidrid is a neonicotinoid insecticide used worldwide and is a nAChR agonist.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 50 mg, 100 mg

### 5-AMAM-2-CP

Cat. No.: HY-136609

5-AMAM-2-CP is a major metabolite of Acetamidrid. Acetamidrid is a neonicotinoid insecticide used worldwide and is a nAChR agonist.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 10 mg, 25 mg











### A-582941 dihydrochloride











Cat. No.: HY-59201A









A-582941 dihydrochloride is a potent, selective and brain-penetrant partial agonist of  $\alpha 7$  nAChR, with  $K_S$  of 10.8 and 16.7 nM in rat brain membranes and human frontal cortex, respectively. A-582941 dihydrochloride also binds to human 5-HT<sub>3</sub> receptor with a  $K_i$  of 150 nM.













**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

<p><b>A-867744</b></p> <p>Cat. No.: HY-12149</p>	<p><b>ABT-107</b></p> <p>Cat. No.: HY-108038</p>
<p>A-867744 is a highly potent and selective type II positive allosteric modulator (PAM) of the <b>alpha7 nicotinic acetylcholine receptors (nAChR)</b> with an <math>EC_{50}</math> of 1.0 <math>\mu</math>M.</p>  <p><b>Purity:</b> 99.92%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg, 100 mg</p>	<p>ABT-107 is a selective <b><math>\alpha 7</math></b> neuronal nicotinic receptor agonist. ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions.</p>  <p><b>Purity:</b> 98.11%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p><b>ABT-418 hydrochloride</b></p> <p>Cat. No.: HY-105170B</p>	<p><b>Acetamiprid</b></p> <p>Cat. No.: HY-B0823</p>
<p>ABT-418 hydrochloride is a potent and selective agonist of <b>nAChRs</b> with cognitive enhancing and anxiolytic activities. ABT-418 hydrochloride activates cholinergic channel and can be used for research of Alzheimer's disease.</p>  <p><b>HCl</b></p> <p><b>Purity:</b> 99.53%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>Acetamiprid is a neonicotinoid insecticide used worldwide. Acetamiprid is a <b>nicotinic acetylcholine receptor (nAChR)</b> agonist, and is shown to be associated with neuromuscular and reproductive disorders.</p>  <p><b>Purity:</b> 99.88%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mM <math>\times</math> 1 mL, 100 mg</p>
<p><b>Acetamiprid-d3</b></p> <p>Cat. No.: HY-B0823S</p>	<p><b>Acetylcholine chloride</b> (ACh chloride)</p> <p>Cat. No.: HY-B0282</p>
<p>Acetamiprid-d3 is the deuterium labeled Acetamiprid. Acetamiprid is a neonicotinoid insecticide. Acetamiprid is a nAChR agonist.</p>  <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>	<p>Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent <b>cholinergic</b> agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs).</p>  <p><b>Purity:</b> <math>\geq</math>98.0%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 10 mM <math>\times</math> 1 mL, 500 mg, 1 g, 5 g</p>
<p><b>Acetylcholine-d4 chloride</b> (ACh-d4 chloride)</p> <p>Cat. No.: HY-B0282S</p>	<p><b>Acetylcholine-d9 chloride</b> (ACh-d9 chloride)</p> <p>Cat. No.: HY-B0282S1</p>
<p>Acetylcholine-d9 (ACh-d9) chloride is the deuterium labeled Acetylcholine chloride. Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent <b>cholinergic</b> agonist.</p>  <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg, 10 mg, 25 mg, 50 mg</p>	<p>Acetylcholine-d9 (ACh-d9) chloride is the deuterium labeled Acetylcholine chloride. Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent <b>cholinergic</b> agonist.</p>  <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg</p>
<p><b>Adiphenine hydrochloride</b></p> <p>Cat. No.: HY-B0379A</p>	<p><b>Adiphenine-d4 hydrochloride</b></p> <p>Cat. No.: HY-B0379AS</p>
<p>Adiphenine hydrochloride is a non-competitive inhibitor of <b>nicotinic acetylcholine receptor (nAChR)</b>, with an <math>IC_{50}</math>s of 1.9, 1.8, 3.7, and 6.3 <math>\mu</math>M for <b><math>\alpha 1</math>, <math>\alpha 3\beta 4</math>, <math>\alpha 4\beta 2</math>, and <math>\alpha 4\beta 4</math></b>, respectively. Adiphenine hydrochloride has anticonvulsant effects.</p>  <p><b>HCl</b></p> <p><b>Purity:</b> 99.77%</p> <p><b>Clinical Data:</b> Launched</p> <p><b>Size:</b> 10 mM <math>\times</math> 1 mL, 100 mg</p>	<p>Adiphenine-d4 hydrochloride is the deuterium labeled Adiphenine hydrochloride. Adiphenine hydrochloride is a non-competitive inhibitor of <b>nicotinic acetylcholine receptor (nAChR)</b>, with an <math>IC_{50}</math>s of 1.9, 1.8, 3.7, and 6.3 <math>\mu</math>M for <b><math>\alpha 1</math>, <math>\alpha 3\beta 4</math>, <math>\alpha 4\beta 2</math>, and <math>\alpha 4\beta 4</math></b>, respectively.</p>  <p><b>HCl</b></p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>

<p><b>Anabaseine</b></p> <p>Cat. No.: HY-115766</p> <p>Anabaseine is a non-selective nicotinic agonist. Anabaseine stimulates all AChRs, preferentially stimulates skeletal muscle and brain <math>\alpha 7</math> subtypes. Anabaseine is also a weak partial agonist at <math>\alpha 4\beta 2</math> nAChRs.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 	<p><b>Anabasine</b>  (S)-Anabasine; (+)-Anabasine</p> <p>Cat. No.: HY-B1532</p> <p>Anabasine ((S)-Anabasine) is an alkaloid that found as a minor component in tobacco (Nicotiana). Anabasine is a botanical pesticide nicotine, acts as a full agonist of nicotinic acetylcholine receptors (nAChRs).</p> <p><b>Purity:</b> 98.57%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p><b>Anabaseine hydrochloride</b>  (S)-Anabasine hydrochloride; (+)-Anabasine hydrochloride</p> <p>Cat. No.: HY-W014928</p> <p>Anabaseine ((S)-Anabasine) hydrochloride is an alkaloid that found as a minor component in tobacco (Nicotiana). Anabaseine is a botanical pesticide nicotine, acts as a full agonist of nicotinic acetylcholine receptors (nAChRs).</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 	<p><b>Anagryne</b>  (-)-Anagryne; Monolupine; Rhombinine</p> <p>Cat. No.: HY-121027</p> <p>Anagryne is an alkaloid that has been found in <i>L. albus</i> and has nematocidal and anticancer activities. It binds to muscarinic and nicotinic acetylcholine receptors (AChRs) with <math>IC_{50}</math> values of 132 and 2096 <math>\mu</math>M respectively.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 5 mg, 10 mg, 25 mg</p> 
<p><b>Anatabine dicitrate</b></p> <p>Cat. No.: HY-19918A</p> <p>Anatabine dicitrate is a tobacco alkaloid that can cross the blood-brain barrier. Anatabine dicitrate is a potent <math>\alpha 4\beta 2</math> nAChR agonist.</p> <p><b>Purity:</b> 99.24%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p><b>Aniracetam</b>  (Ro 13-5057)</p> <p>Cat. No.: HY-10932</p> <p>Aniracetam (Ro 13-5057) is a nootropic and neuroprotective drug, which is selectively modulates the AMPA receptor and nAChR. Target: AMPA; nAChR. Aniracetam is an ampakine and nootropic of the racetam chemical class purported to be considerably more potent than piracetam.</p> <p><b>Purity:</b> 99.89%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 500 mg, 1 g, 5 g</p> 
<p><b>AR-R17779 hydrochloride</b></p> <p>Cat. No.: HY-135483A</p> <p>AR-R17779 hydrochloride is a potent and selective full agonist of nAChR, with <math>K_{1/2}</math> of 92 and 16000 nM for <math>\alpha 7</math> and <math>\alpha 4\beta 2</math> subtype, respectively. AR-R17779 hydrochloride can improve learning and memory in rats. AR-R17779 hydrochloride also has anxiolytic activity.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 	<p><b>Asoxime dichloride</b>  (HI-6)</p> <p>Cat. No.: HY-106901A</p> <p>Asoxime dichloride (HI-6) is an antagonist to acetylcholine receptors (AChRs) including the nicotinic receptor, <math>\alpha 7</math> nAChR. Asoxime dichloride involves in modulating immunity response.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 
<p><b>Asoxime-d4 dichloride</b>  (HI-6-d4)</p> <p>Cat. No.: HY-106901AS</p> <p>Asoxime-d4 dichloride (HI-6-d4) is the deuterium labeled Asoxime dichloride. Asoxime dichloride (HI-6) is an antagonist to acetylcholine receptors (AChRs) including the nicotinic receptor, <math>\alpha 7</math> nAChR. Asoxime dichloride involves in modulating immunity response.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p> 	<p><b>Atracurium besylate</b>  (BW-33A)</p> <p>Cat. No.: HY-B0292A</p> <p>Atracurium Besylate is a neuromuscular blocking agent with ED95 of 0.2 mg/kg.</p> <p><b>Purity:</b> 98.89%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 50 mg, 100 mg, 500 mg</p> 


<p><b>Benzethonium chloride</b></p> <p>Cat. No.: HY-B0942</p> <p>Benzethonium chloride inhibit human recombinant <math>\alpha 7</math> and <math>\alpha 4\beta 2</math> neuronal nicotinic acetylcholine receptors in <i>Xenopus</i> oocytes.</p>  <p><b>Purity:</b> <math>\geq 98.0\%</math>  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 100 mg</p>	<p><b>Benzethonium-d7 chloride</b></p> <p>Cat. No.: HY-B0942S</p> <p>Benzethonium-d7 chloride is the deuterium labeled Benzethonium chloride. Benzethonium chloride inhibit human recombinant <math>\alpha 7</math> and <math>\alpha 4\beta 2</math> neuronal nicotinic acetylcholine receptors in <i>Xenopus</i> oocytes.</p>  <p><b>Purity:</b> <math>&gt; 98\%</math>  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Benzoquinonium dibromide</b></p> <p>Cat. No.: HY-B1552B</p> <p>Benzoquinonium dibromide is a <b>nicotinic acetylcholine receptors (nAChRs)</b> antagonist, with an <math>IC_{50}</math> of 0.46 <math>\mu M</math>. Benzoquinonium dibromide can block neuromuscular and ganglionic transmission.</p>  <p><b>Purity:</b> <math>&gt; 98\%</math>  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>BNC210</b> (H-Ile-Trp-OH; IW-2143)</p> <p>Cat. No.: HY-105858</p> <p>BNC210 (H-Ile-Trp-OH; IW-2143) is a <math>\alpha 7</math> nAChR negative allosteric modulator. BNC210 has potent activity in animal models of anxiety and depression.</p>  <p><b>Purity:</b> 98.10%  <b>Clinical Data:</b> Phase 2  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg, 100 mg, 500 mg</p>
<p><b>BNC375</b></p> <p>Cat. No.: HY-128575</p> <p>BNC375 is a potent, selective, and orally available type I positive allosteric modulator of <math>\alpha 7</math> nAChRs with an <math>EC_{50}</math> of 1.9 <math>\mu M</math>. BNC375 exhibits good CNS-drug like properties and clinical candidate potential. .</p>  <p><b>Purity:</b> 99.64%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p><b>Br-PBTC</b></p> <p>Cat. No.: HY-103066</p> <p>Br-PBTC is a potent, 2/4 subtype-selective positive allosteric modulator of nAChRs (nicotinic acetylcholine receptors) with <math>\alpha 2\beta 2\alpha 2\beta 4\alpha 4\beta 2\alpha 4\beta 4(\alpha 4\beta 2)_2\alpha 4</math> and <math>(\alpha 4\beta 2)_2\beta 2</math> <math>EC_{50}</math> ranges from 0.1~0.6 <math>\mu M</math>. Br-PBTC acts from the c-tail of an <math>\alpha</math> subunit.</p>  <p><b>Purity:</b> <math>&gt; 98\%</math>  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Bradanicline</b> (TC-5619)</p> <p>Cat. No.: HY-18060</p> <p>Bradanicline is a highly selective <math>\alpha 7</math> nicotinic acetylcholine receptor (nAChR) agonist (humana <math>\alpha 7</math> nAChR: <math>EC_{50}=17</math> nM; <math>K_i=1.4</math> nM). Bradanicline is used for the research of cognitive disorders.</p>  <p><b>Purity:</b> 99.04%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p><b>Catestatin</b></p> <p>Cat. No.: HY-P1271</p> <p>Catestatin is a 21-amino acid residue, cationic and hydrophobic peptide. Catestatin is an endogenous peptide that regulates cardiac function and blood pressure.</p> <p>RSMRLSFRARGYGFRGPGQLQL</p> <p><b>Purity:</b> <math>&gt; 98\%</math>  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Catestatin TFA</b></p> <p>Cat. No.: HY-P1271A</p> <p>Catestatin TFA is a 21-amino acid residue, cationic and hydrophobic peptide. Catestatin TFA is an endogenous peptide that regulates cardiac function and blood pressure.</p> <p>RSMRLSFRARGYGFRGPGQLQL (TFA salt)</p> <p><b>Purity:</b> 99.68%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 5 mg, 10 mg, 25 mg</p>	<p><b>CCMI</b> (AVL-3288; UCI-4083)</p> <p>Cat. No.: HY-12150</p> <p>CCMI (AVL-3288) is a potent and selective <math>\alpha 7</math> nAChR-positive allosteric modulator, does not bind to or activate <math>\alpha 7</math> nAChRs via the orthosteric site, and causes significant positive modulation of agonist-induced currents at <math>\alpha 7</math> nAChRs.</p>  <p><b>Purity:</b> 99.93%  <b>Clinical Data:</b> Phase 1  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg</p>

<p><b>Chlorisondamine diiodide</b></p> <p><b>Cat. No.:</b> HY-101347</p> <p>Chlorisondamine (diiodide) is a potent <b>nicotinic acetylcholine receptor (nAChR)</b> antagonist and a ganglion blocker. Chlorisondamine antagonizes some of nicotine's central actions in a potent, long-lasting and pharmacologically selective way.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Cholesterol myristate</b> (Cholesteryl myristate; Cholesteryl tetradecanoate)</p> <p><b>Cat. No.:</b> HY-N2338</p> <p>Cholesterol myristate is a natural steroid present in traditional Chinese medicine. Cholesterol myristate binds to several ion channels such as the <b>nicotinic acetylcholine receptor</b>, <b>GABAA receptor</b>, and the inward-rectifier <b>potassium ion channel</b>.</p>  <p><b>Purity:</b> ≥98.0%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 250 mg</p>
<p><b>Cisatracurium besylate</b> (51W89)</p> <p><b>Cat. No.:</b> HY-13596</p> <p>Cisatracurium besylate (51W89) is a nondepolarizing neuromuscular blocking agent, antagonizing the action of acetylcholine by inhibiting neuromuscular transmission.</p>  <p><b>Purity:</b> ≥98.0%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM × 1 mL, 25 mg, 50 mg, 100 mg</p>	<p><b>Coclaurine</b></p> <p><b>Cat. No.:</b> HY-N3610</p> <p>Coclaurine is a class of tetrahydroisoquinoline alkaloids isolated from <i>Sarcopetalum harveyanum</i>. Coclaurine is a <b>nicotinic acetylcholine receptor (nAChRs)</b> antagonist.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 5 mg</p>
<p><b>COG 133</b></p> <p><b>Cat. No.:</b> HY-P1050</p> <p>COG 133 is a fragment of Apolipoprotein E (APOE) peptide. COG 133 competes with the ApoE holoprotein for binding the LDL receptor, with potent anti-inflammatory and neuroprotective effects. COG 133 is also a <b>nAChR</b> antagonist with an <math>IC_{50}</math> of 445 nM.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>COG 133 TFA</b></p> <p><b>Cat. No.:</b> HY-P1050A</p> <p>COG 133 TFA is a fragment of Apolipoprotein E (APOE) peptide. COG 133 TFA competes with the ApoE holoprotein for binding the LDL receptor, with potent anti-inflammatory and neuroprotective effects. COG 133 TFA is also a <b>nAChR</b> antagonist with an <math>IC_{50}</math> of 445 nM.</p>  <p><b>Purity:</b> 98.00%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg, 10 mg</p>
<p><b>CP-601927</b></p> <p><b>Cat. No.:</b> HY-138879</p> <p>CP-601927 is a selective <math>\alpha 4\beta 2</math> nicotinic acetylcholine receptor (nAChR) partial agonist (<math>K_i=1.2</math> nM; <math>EC_{50}=2.6</math> <math>\mu</math>M). CP-601927 shows good brain penetration and antidepressant-like properties.</p>  <p><b>Purity:</b> 98.28%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p><b>CP-601932</b> (1S,5R)-CP-601927)</p> <p><b>Cat. No.:</b> HY-138879B</p> <p>CP-601932 ((1S,5R)-CP-601927) is a high-affinity partial agonist at <math>\alpha 3\beta 4</math> nAChR (<math>K_i=21</math>nM; <math>EC_{50}\sim 3</math><math>\mu</math>M). CP-601932 has the same high-binding affinity at <math>\alpha 4\beta 2</math> nAChR (<math>K_i=21</math>nM) and an order of magnitude lower affinity for <math>\alpha 6</math> and <math>\alpha 7</math> nAChR subtypes.</p>  <p><b>Purity:</b> 99.74%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p><b>Cyclodrine hydrochloride</b></p> <p><b>Cat. No.:</b> HY-U00139</p> <p>Cyclodrine hydrochloride is a cholinergic (muscarinic, nicotinic) (<b>mAChR</b> and <b>nAChR</b>) receptor antagonist.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Cytisinicline</b> (Cytisine; Sophorine; Baptitoxine)</p> <p><b>Cat. No.:</b> HY-N0175</p> <p>Cytisinicline (Cytisine) is an alkaloid that occurs naturally in several plant genera, such as <i>Laburnum</i> and <i>Cytisus</i>. Cytisinicline (Cytisine) is a partial agonist of <math>\alpha 4\beta 2</math> nAChRs, and partial to full agonist at <math>\beta 4</math> containing receptors and <math>\alpha 7</math> receptors.</p>  <p><b>Purity:</b> ≥98.0%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM × 1 mL, 25 mg</p>

## D-Tubocurarine chloride pentahydrate

Cat. No.: HY-125901

D-Tubocurarine chloride pentahydrate is the chloride salt form of Tubocurarine, a **nicotinic acetylcholine receptors (AChR)** antagonist, and can be used as a skeletal muscle relaxant during surgery or mechanical ventilation.




**Purity:** 99.68%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 10 mg

## Decamethonium Bromide

Cat. No.: HY-B0570

Decamethonium Bromide is a nicotinic AChR partial agonist and neuromuscular blocking agent. Target: nAChR Decamethonium (Syncurine) is a depolarizing muscle relaxant or neuromuscular blocking agent, and is used in anesthesia to induce paralysis.




**Purity:** ≥98.0%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 500 mg, 5 g, 10 g

## Desformylflustrabromine hydrochloride

(Deformylflustrabromine hydrochloride; dFBr hydrochloride) Cat. No.: HY-107675

Desformylflustrabromine hydrochloride is a selective agonist of  $\alpha_7\beta_2$  neuronal nicotinic acetylcholine receptor (nAChR) with a  $pEC_{50}$  of 6.48.




**Purity:** 99.77%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## Dianicline dihydrochloride

Cat. No.: HY-110241

Dianicline dihydrochloride is a  $\alpha_4\beta_2$  **nicotinic acetylcholine receptor** partial agonist, a class of drugs that includes varenicline and cytisine for smoking cessation. Dianicline dihydrochloride increases cessation rates in a dose-dependent manner.




**Purity:** 99.42%  
**Clinical Data:**  
**Size:** 1 mg, 5 mg

## Dicloromezotiaz

Cat. No.: HY-145298

Dicloromezotiaz is a potent insecticide acting on **nicotinic acetylcholine receptors (nAChRs)**. Dicloromezotiaz can be used to control a broad range of lepidoptera.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

## Dihydro- $\beta$ -erythroidine hydrobromide

(DH $\beta$ E hydrobromide)

Cat. No.: HY-107670

Dihydro- $\beta$ -erythroidine (DH $\beta$ E) hydrobromide is a potent, orally active, and competitive antagonist of neuronal nAChRs. Dihydro- $\beta$ -erythroidine hydrobromide shows selectivity for  $\alpha_4\beta_4$  and  $\alpha_4\beta_2$  nAChRs, with  $IC_{50}$ s of 0.19 and 0.37  $\mu$ M, respectively. Antidepressant-like activities.




**Purity:** 99.84%  
**Clinical Data:** No Development Reported  
**Size:** 5 mg, 10 mg

## Dinotefuran

(MTI-446)

Cat. No.: HY-B0827

Dinotefuran is an insecticide of the neonicotinoid class, its mechanism of action involves disruption of the insect's nervous system by inhibiting nicotinic acetylcholine receptors. Target: nAChR, Antiparasitic.




**Purity:** 98.88%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 50 mg, 100 mg

## DPNB-ABT594

Cat. No.: HY-131001

DPNB-ABT594 is a nitrobenzyl-caged ABT594 (HY-14316A) and activates nAChRs containing the  $\alpha_4\beta_2$  subunits with good selectivity than the  $\alpha_7$  subunit.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

## Encenicline

(EVP-6124)

Cat. No.: HY-15430

Encenicline (EVP-6124) is a novel partial agonist of  $\alpha_7$  neuronal nicotinic acetylcholine receptors (nAChRs).




**Purity:** >98%  
**Clinical Data:** Phase 3  
**Size:** 1 mg, 5 mg

## Encenicline hydrochloride

(EVP-6124 hydrochloride)

Cat. No.: HY-15430A

Encenicline hydrochloride (EVP-6124 hydrochloride) is a novel partial agonist of  $\alpha_7$  neuronal nicotinic acetylcholine receptors (nAChRs).























**Purity:** 98.82%  
**Clinical Data:** Phase 3  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg



<p><b>Epiboxidine</b></p> <p style="text-align: right;"><b>Cat. No.:</b> HY-138953</p> <p>Epiboxidine is a potent and selective <b>neural nAChR</b> agonist with <math>K_S</math> of 0.46 nM and 1.2 nM for <b>rat</b> and <b>human <math>\alpha4\beta2</math> nAChRs</b>, respectively. Epiboxidine is a methylisoxazole analog of the alkaloid Epibatidine, and is also an analog of another nAChR agonist, ABT 418.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Facincline hydrochloride</b> (RG3487 hydrochloride)</p> <p style="text-align: right;"><b>Cat. No.:</b> HY-108057A</p> <p>Facincline hydrochloride (RG3487 hydrochloride) is an orally active <b>nicotinic <math>\alpha7</math> receptor</b> partial agonist, with a <math>K_i</math> of 6 nM for <math>\alpha7</math> human nAChR. Facincline hydrochloride (RG3487 hydrochloride) improves cognition and sensorimotor gating in rodents.</p> <p><b>Purity:</b> 99.93%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>
<p><b>Ferulamide</b></p> <p style="text-align: right;"><b>Cat. No.:</b> HY-N3894</p> <p>Ferulamide is a Ferulic acid derivative isolated from <i>Portulaca oleracea</i> L. with anticholinesterase activities.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg, 10 mg</p>	<p><b>Flupyradifurone</b></p> <p style="text-align: right;"><b>Cat. No.:</b> HY-145295</p> <p>Flupyradifurone is a systemic <b>nAChR</b> agonist that interferes with signal transduction in the central nervous system of sucking pests. Flupyradifurone can be used as a butenolide insecticide.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Flupyrimin</b></p> <p style="text-align: right;"><b>Cat. No.:</b> HY-145297</p> <p>Flupyrimin acts as an antagonist at the insect nicotinic acetylcholine receptor (<b>nAChR</b>).</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p><b>Galanthamine hydrobromide</b> (Galantamine hydrobromide)</p> <p style="text-align: right;"><b>Cat. No.:</b> HY-A0009</p> <p>Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid <b>AChE</b> inhibitor, with an <math>IC_{50}</math> of 0.35 <math>\mu</math>M.</p> <p><b>Purity:</b> 99.93%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 50 mg, 100 mg</p>
<p><b>Galanthamine-d3 hydrobromide</b> (Galantamine-d3 hydrobromide)</p> <p style="text-align: right;"><b>Cat. No.:</b> HY-A0009S</p> <p>Galanthamine-d3 (hydrobromide) is deuterium labeled Galanthamine (hydrobromide). Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an <math>IC_{50}</math> of 0.35 <math>\mu</math>M.</p> <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>	<p><b>GTS-21 dihydrochloride</b> (DMXB-A; DMXB-anabaseine)</p> <p style="text-align: right;"><b>Cat. No.:</b> HY-14564A</p> <p>GTS-21 dihydrochloride is a selective <math>\alpha7</math> nicotinic acetylcholine receptor (<b><math>\alpha7</math>-nAChR</b>) agonist with antiinflammatory and cognitionenhancing activities.</p> <p><b>Purity:</b> 99.78%  <b>Clinical Data:</b> Phase 2  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>
<p><b>Hexamethonium Bromide</b></p> <p style="text-align: right;"><b>Cat. No.:</b> HY-B0569</p> <p>Hexamethonium Bromide is a non-selective ganglionic <b>nicotinic-receptor antagonist</b> (nAChR) antagonist, with mixed competitive and noncompetitive activity. Hexamethonium Bromide has anti-hypertensive activity.</p> <p><b>Purity:</b> <math>\geq</math>98.0%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 500 mg, 1 g, 5 g</p>	<p><b>Iptakalim hydrochloride</b></p> <p style="text-align: right;"><b>Cat. No.:</b> HY-108069</p> <p>Iptakalim hydrochloride, a lipophilic para-amino compound, is a novel ATP-sensitive potassium channel (<math>K_{ATP}</math>) opener, as well as an <math>\alpha_4\beta_2</math>-containing <b>nicotinic acetylcholine receptor</b> (nAChR) antagonist.</p> <p><b>Purity:</b> <math>\geq</math>98.0%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 25 mg, 50 mg</p>











<p><b>Ispronnicline</b> (TC-1734; ACD3480)</p> <p>Ispronnicline (TC-1734), an orally active, brain-selective <math>\alpha 4\beta 2</math> nicotine acetylcholine receptor (nAChR) partial agonist, has shown memory-enhancing properties in rodents and a good tolerability profile.</p> <p><b>Purity:</b> 98.38% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p><b>Lobeline hydrochloride</b> (<math>\alpha</math>-Lobeline hydrochloride; L-Lobeline hydrochloride)</p> <p>Lobeline hydrochloride, a nicotinic receptor agonist, acting as a potent antagonist at both <math>\alpha 3\beta 2</math> and <math>\alpha 4\beta 2</math> neuronal nicotinic receptor subtypes.</p> <p><b>Purity:</b> 99.97% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 50 mg, 100 mg</p>
<p><b>LtIA-F</b></p> <p>LtIA-F, a novel fluorescent analogue of LtIA, provides a wealth of pharmacological tools to explore the structure-function relationship, distribution, and ligand binding domain of the <math>\alpha 3\beta 2</math> nAChR subtype.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Mecamylamine hydrochloride</b></p> <p>Mecamylamine hydrochloride is an orally active, nonselective, noncompetitive nAChR antagonist that can treat various neuropsychiatric disorders. Mecamylamine hydrochloride is originally used as a ganglionic blocker in treating hypertension.</p> <p><b>Purity:</b> <math>\geq</math>98.0% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg</p>
<p><b>Mecamylamine hydrochloride-13C4,15N</b></p> <p>Mecamylamine hydrochloride-13C4,15N is the <sup>13</sup>C-labeled and <sup>15</sup>N-labeled Mecamylamine hydrochloride. Mecamylamine hydrochloride is an orally active, nonselective, noncompetitive nAChR antagonist that can treat various neuropsychiatric disorders.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Mecamylamine-d3 hydrochloride</b></p> <p>Mecamylamine-d3 hydrochloride is the deuterium labeled Mecamylamine hydrochloride. Mecamylamine hydrochloride is an orally active, nonselective, noncompetitive nAChR antagonist that can treat various neuropsychiatric disorders.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 1 mg, 10 mg</p>
<p><b>Meclofenoxate hydrochloride</b></p> <p>Meclofenoxate hydrochloride, an ester of dimethylethanolamine (DMAE) and 4-chlorophenoxyacetic acid (pCPA), has been shown to improve memory, have a mentally stimulating effect, and improve general cognition.</p> <p><b>Purity:</b> 98.80% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 100 mg</p>	<p><b>Methyllycaconitine citrate</b> (MLA)</p> <p>Methyllycaconitine citrate is a specific antagonist of <math>\alpha 7</math> neuronal nicotinic acetylcholine receptor (<math>\alpha 7</math>nAChR).</p> <p><b>Purity:</b> 99.58% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg</p>
<p><b>MG624</b> (Stilonium iodide)</p> <p>MG624 is a potent and selective neuronal <math>\alpha 7</math> nAChR antagonist with a <math>K_i</math> of 106 nM.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Mivacurium dichloride</b></p> <p>Mivacurium dichloride is a benzyloisoquinoline derivative and is a short-acting non-depolarizing neuromuscular blocking agent and skeletal muscle relaxant.</p> <p><b>Purity:</b> 99.35% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>











<p><b>Monepantel</b> (AAD1566)</p> <p>Cat. No.: HY-14774</p> <p>Monepantel is organic anthelmintic, and acts as a positive allosteric modulator of a nematode-specific clade of nicotinic acetylcholine receptor (nAChR) subunits.</p>  <p><b>Purity:</b> 99.68% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg</p>	<p><b>Myosmine</b></p> <p>Cat. No.: HY-W001909</p> <p>Myosmine, a specific tobacco alkaloid in nuts and nut products, has low affinity for <math>\alpha 4\beta 2</math> nicotinic acetylcholinergic receptors (nAChR) with a <math>K_i</math> of 3300 nM.</p>  <p><b>Purity:</b> 99.95% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 100 mg, 250 mg</p>
<p><b>Myosmine-d4</b></p> <p>Cat. No.: HY-W001909S</p> <p>Myosmine-d4 is the deuterium labeled Myosmine. Myosmine, a specific tobacco alkaloid in nuts and nut products, has low affinity for <math>\alpha 4\beta 2</math> nicotinic acetylcholinergic receptors (nAChR) with a <math>K_i</math> of 3300 nM.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>N-Methylcytisine</b> (Caulophylline)</p> <p>Cat. No.: HY-N0443</p> <p>N-Methylcytisine (Caulophylline), a tricyclic quinolizidine alkaloid, exerts hypoglycaemic, analgesic and anti-inflammatory activities.</p>  <p><b>Purity:</b> 99.67% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 20 mg</p>
<p><b>nAChR agonist 1</b></p> <p>Cat. No.: HY-133011</p> <p>nAChR agonist 1 is a potent, brain-permeable, and orally efficacious positive allosteric modulator of <math>\alpha 7</math> nicotinic acetylcholine receptor (<math>\alpha 7</math> nAChR).</p>  <p><b>Purity:</b> 98.02% <b>Clinical Data:</b> Phase 1 <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg</p>	<p><b>nAChR agonist 2</b></p> <p>Cat. No.: HY-115764</p> <p>nAChR agonist 2 (compound 8) is a selective <math>\alpha 4\beta 2</math> (<math>\alpha 4\beta 2</math>) nAChR agonist (<math>K_d=26</math> nM).</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>nAChR agonist CMPI hydrochloride</b></p> <p>Cat. No.: HY-136258</p> <p>nAChR agonist CMPI hydrochloride is a potent and selective positive allosteric modulator (PAM) of nAChR containing a <math>\alpha 4:\alpha 4</math> subunit interface. nAChR agonist CMPI hydrochloride enhances the response of (<math>\alpha 4</math>)<sub>2</sub>(<math>\beta 2</math>)<sub>2</sub> nAChR to ACh (10 <math>\mu</math>M) with an <math>EC_{50}</math> of 0.26 <math>\mu</math>M.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>nAChR antagonist 1</b></p> <p>Cat. No.: HY-146405</p> <p>nAChR antagonist 1 (compound B15) is an excellent <math>\alpha 7</math> nAChR antagonist with an <math>IC_{50}</math> value of 3.3 <math>\mu</math>M. nAChR antagonist 1 can be used for researching schizophrenia, Alzheimer's disease and inflammatory disorders.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>nAChR modulator-1</b></p> <p>Cat. No.: HY-145299</p> <p>nAChR modulator-1, an insecticide, is an insect nAChR orthosteric modulator.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>nAChR modulator-2</b></p> <p>Cat. No.: HY-145300</p> <p>nAChR modulator-2, an insecticide, is an insect nAChR orthosteric modulator.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>

<p><b>Nelonicline</b> (ABT-126)</p> <p>Cat. No.: HY-16748</p> <p>Nelonicline (ABT-126) is an orally active and selective <math>\alpha 7</math> <b>nicotinic receptor</b> agonist with high affinity to <math>\alpha 7</math> nAChRs in human brain (<math>K_i=12.3</math> nM). Nelonicline is used for the research of schizophrenia and Alzheimer's disease.</p>  <p><b>Purity:</b> 99.45% <b>Clinical Data:</b> Phase 2 <b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p><b>Nelonicline citrate</b> (ABT-126 citrate)</p> <p>Cat. No.: HY-16748A</p> <p>Nelonicline (ABT-126) citrate is an orally active and selective <math>\alpha 7</math> <b>nicotinic receptor</b> agonist with high affinity to <math>\alpha 7</math> nAChRs in human brain (<math>K_i=12.3</math> nM). Nelonicline citrate is used for the research of schizophrenia and Alzheimer's disease.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Nitenpyram</b></p> <p>Cat. No.: HY-B0820</p> <p>Nitenpyram is a calss of neonicotinoid and an insect <b>nicotinic acetylcholine receptor (nAChR)</b> agonist with an <math>IC_{50}</math> of 14 nM. Nitenpyram is an oral fast-acting insecticide used to suppress sucking insects on companion animals.</p>  <p><b>Purity:</b> 99.20% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 100 mg</p>	<p><b>NS 1738</b> (NSC 213859)</p> <p>Cat. No.: HY-12151</p> <p>NS 1738 (NSC 213859) is a novel positive allosteric modulator of the <math>\alpha 7</math> <b>nAChR</b>, with respect to positive modulation of <math>\alpha 7</math> nAChR (<math>EC_{50}=3.4</math> <math>\mu</math>M in oocyte experiments).</p>  <p><b>Purity:</b> 99.91% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p><b>NS 9283</b></p> <p>Cat. No.: HY-110168</p> <p>NS9283 is a positive positive allosteric modulator of (<math>\alpha 4</math>)<sub>3</sub>(<math>\beta 2</math>)<sub>2</sub> <b>nicotinic ACh receptors</b>. NS9283 can be used in a series of neurological conditions such as attention deficit hyperactivity disorder (ADHD), schizophrenia, Parkinson's disease and Alzheimer's disease.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>NS3861</b></p> <p>Cat. No.: HY-110121A</p> <p>NS3861 is an agonist of nicotinic acetylcholine receptors (<b>nAChRs</b>) and binds with high affinity to heteromeric <math>\alpha 3\beta 4</math> <b>nAChR</b>. The binding <math>K_i</math> values of 0.62, 25, 7.8, 55 nM for <math>\alpha 3\beta 4</math>, <math>\alpha 3\beta 2</math>, <math>\alpha 4\beta 4</math>, <math>\alpha 4\beta 2</math>, respectively.</p>  <p><b>Purity:</b> 99.59% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p><b>NS3861 fumarate</b></p> <p>Cat. No.: HY-110121</p> <p>NS3861 fumarate is an agonist of nicotinic acetylcholine receptors (<b>nAChRs</b>) and binds with high affinity to heteromeric <math>\alpha 3\beta 4</math> <b>nAChR</b>. The binding <math>K_i</math> values of 0.62, 25, 7.8, 55 nM for <math>\alpha 3\beta 4</math>, <math>\alpha 3\beta 2</math>, <math>\alpha 4\beta 4</math>, <math>\alpha 4\beta 2</math>, respectively.</p>  <p><b>Purity:</b> 99.45% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p><b>Oxantel</b> (CP-14445)</p> <p>Cat. No.: HY-124498</p> <p>Oxantel (CP-14445), a m-oxyphenol derivative of Pyrantel (HY-12641), is a N-subtype <b>AChR</b> agonist. Oxantel is an anthelmintic, with excellent trichuricidal properties.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Pancuronium dibromide</b></p> <p>Cat. No.: HY-B0429</p> <p>Pancuronium dibromide, a bis-quaternary steroid, is a neuromuscular relaxant. Pancuronium dibromide inhibits neuromuscular transmission by competing with acetylcholine for binding sites on <b>nACh receptors</b>.</p>  <p><b>Purity:</b> <math>\geq</math>98.0% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg, 100 mg</p>	<p><b>PHA 568487</b></p> <p>Cat. No.: HY-107666</p> <p>PHA 568487 a selective agonist of alpha-7 nicotinic acetylcholine receptor (<math>\alpha</math>-7 <b>nAChR</b>).PHA 568487 reduces neuroinflammation and oxidative stress. PHA-568487 has rapid brain penetration.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg</p>



<p><b>PHA 568487 free base</b></p> <p>Cat. No.: HY-129674</p>	<p><b>PHA-543613</b></p> <p>Cat. No.: HY-105670</p>
<p>PHA 568487 free base is a selective <math>\alpha 7</math> nicotinic acetylcholine receptor (<math>\alpha 7</math> nAChR) agonist. PHA 568487 free base reduces neuroinflammation.</p> <p><b>Purity:</b> 99.52%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>PHA-543613 is a potent, orally active, brain-penetrant and selective <math>\alpha 7</math> nAChR agonist with a <math>K_i</math> of 8.8 nM. PHA-543613 displays selectivity for <math>\alpha 7</math>-nAChR over <math>\alpha 3\beta 4</math>, <math>\alpha 1\beta 1\gamma \delta</math>, <math>\alpha 4\beta 2</math> and 5-HT<sub>3</sub> receptors.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>
<p><b>Pipecuronium bromide</b></p> <p>Cat. No.: HY-B0743A</p>	<p><b>PNU-120596 (NSC 216666)</b></p> <p>Cat. No.: HY-12152</p>
<p>Pipecuronium bromide is a potent long-acting nondepolarizing steroidal neuromuscular blocking agent (NMBA), and a bisquaternary ammonium compound. Pipecuronium bromide is a powerful competitive nAChR antagonist with a <math>K_d</math> of 3.06 <math>\mu</math>M.</p> <p><b>Purity:</b> 95.01%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 5 mg</p>	<p>PNU-120596 (NSC 216666) is a potent and selective <math>\alpha 7</math> nAChR positive allosteric modulator (PMA) with an <math>EC_{50}</math> of 216 nM. PNU-120596 is inactive against <math>\alpha 4\beta 2</math>, <math>\alpha 3\beta 4</math>, and <math>\alpha 9\alpha 10</math> nAChRs. PNU-120596 has the potential for psychiatric and neurological disorders research.</p> <p><b>Purity:</b> 99.83%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg, 100 mg</p>
<p><b>PNU-282987</b></p> <p>Cat. No.: HY-12560A</p>	<p><b>PNU-282987 free base</b></p> <p>Cat. No.: HY-12560</p>
<p>PNU-282987 is a selective <math>\alpha 7</math> nicotinic acetylcholine receptor (<math>\alpha 7</math> nAChR) agonist with <math>K_i</math> of 26 nM; no affinity for <math>\alpha 1\beta 1\gamma \delta</math> and <math>\alpha 3\beta 4</math> nAChRs (<math>IC_{50} \geq 60 \mu</math>M).</p> <p><b>Purity:</b> 99.70%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg, 100 mg</p>	<p>PNU-282987 (free base) (Compound C7) is a potent <math>\alpha 7</math> nicotinic acetylcholine receptor (nAChR) agonist with an <math>EC_{50}</math> of 154 nM. PNU-282987 (free base) is also a functional antagonist of the 5-HT<sub>3</sub> receptor with an <math>IC_{50}</math> of 4541 nM.</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>
<p><b>PNU-282987 S enantiomer free base</b></p> <p>Cat. No.: HY-12560D</p>	<p><b>Pozanicline (ABT-089)</b></p> <p>Cat. No.: HY-14565</p>
<p>PNU-282987 S enantiomer free base is the S-enantiomer of PNU-282987 free base. PNU-282987 is an <math>\alpha 7</math> nicotinic acetylcholine receptor (<math>\alpha 7</math> nAChR) agonist.</p> <p><b>Purity:</b> 99.58%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mM <math>\times</math> 1 mL, 2 mg, 5 mg</p>	<p>Pozanicline (ABT-089) selectively activate neuronal nicotinic acetylcholine receptor (nAChR) subtypes, is a novel cholinergic agent that is a partial agonist at <math>\alpha 4\beta 2^*</math> nAChRs (<math>K_i=16</math> nM) and shows high selectivity for <math>\alpha 6\beta 2^*</math> and <math>\alpha 4\alpha 5\beta 2</math> nAChR subtypes, the binding affinity (<math>K_i</math>, rat)...</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> Phase 2</p> <p><b>Size:</b> 1 mg, 5 mg</p>
<p><b>Pozanicline dihydrochloride (ABT-089 dihydrochloride)</b></p> <p>Cat. No.: HY-110160</p>	<p><b>PSEM 89S TFA</b></p> <p>Cat. No.: HY-112217A</p>
<p>Pozanicline dihydrochloride (ABT-089 dihydrochloride) is an orally bioavailable nicotinic acetylcholine receptor (nAChR) agonist with a <math>K_i</math> of 16.7 nM for binding to [<sup>3</sup>H]cytisine sites.</p> <p><b>Purity:</b> 97.96%</p> <p><b>Clinical Data:</b> Phase 2</p> <p><b>Size:</b> 5 mg, 10 mg</p>	<p>PSEM 89S TFA is a selective and brain penetrant agonists for the resulting ion channels. PSEM 89S TFA is orthogonally selective for Q79G and L141F, respectively.</p> <p><b>Purity:</b> 99.81%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>

<p><b>Rivanicline</b> (RJR-2403; (E)-Metanicotine)</p> <p>Rivanicline (RJR-2403; (E)-Metanicotine) is a <b>neuronal nicotinic receptor</b> agonist, showing high selectivity for the <math>\alpha 4\beta 2</math> subtype (<math>K_i=26</math> nM); &gt; 1,000 fold selectivity than <math>\alpha 7</math> receptors(<math>K_i= 36000</math> nM).</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Rivanicline hemioxalate</b> (RJR-2403 hemioxalate; (E)-Metanicotine hemioxalate)</p> <p>Rivanicline hemioxalate (RJR-2403 hemioxalate; (E)-Metanicotine hemioxalate) is a <b>neuronal nicotinic receptor</b> agonist, showing high selectivity for the <math>\alpha 4\beta 2</math> subtype (<math>K_i=26</math> nM); &gt; 1,000 fold selectivity than <math>\alpha 7</math> receptors(<math>K_i= 3.6</math> <math>\mu</math>M).</p> <p><b>Purity:</b> <math>\geq 95.0\%</math> <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 50 mg</p>
<p><b>Rivanicline oxalate</b> (RJR-2403 oxalate; (E)-Metanicotine oxalate)</p> <p>Rivanicline oxalate (RJR-2403 oxalate; (E)-Metanicotine oxalate) is a <b>neuronal nicotinic receptor</b> agonist, showing high selectivity for the <math>\alpha 4\beta 2</math> subtype (<math>K_i=26</math> nM); &gt; 1,000 fold selectivity than <math>\alpha 7</math> receptors(<math>K_i= 3.6</math> <math>\mu</math>M).</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>RJR-2429 dihydrochloride</b></p> <p>RJR 2429 hydrochloride is a <b><math>\alpha 4\beta 2</math> and <math>\alpha 7</math> nAChR</b> agonist.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Roanicant</b> (SUVN-911 free base)</p> <p>Roanicant (SUVN-911 free base) is a novel, potent, selective, and orally active <b>neuronal nicotinic acetylcholine <math>\alpha 4\beta 2</math> receptor</b> antagonist for the research of depression.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>S 24795</b></p> <p>S 24795 is a partial agonist of <b><math>\alpha 7</math> nAChR</b> and improves mnemonic function in aged mice for the treatment of aging-related memory disturbances.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>S-(+)-Mecamylamine hydrochloride</b> (Dexmecamylamine hydrochloride; TC-5214 hydrochloride)</p> <p>S-(+)-Mecamylamine (hydrochloride) is a <b>neuronal nicotinic receptor</b> modulator with antidepressant activity.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>S16961</b> (S169611)</p> <p>S16961 is a <b>nicotinic receptor</b> agonist.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>SEN12333</b> (WAY-317538)</p> <p>SEN 12333 (WAY-317538) is a potent, selective and orally active <b><math>\alpha 7</math> nAChR</b> agonist. SEN12333 displays high affinity for the rat <math>\alpha 7</math> nAChRs expressed in GH4C1 cells (<math>K_{i1}=260</math> nM) and acts as full agonist in functional <math>Ca^{2+}</math> flux studies (<math>EC_{50}=1.6</math> <math>\mu</math>M).</p> <p><b>Purity:</b> 98.45% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p><b>SIB-1553A</b></p> <p>SIB-1553A is an orally bioavailable <b>nicotinic acetylcholine receptors (nAChRs)</b> agonist, with selectivity for <math>\beta 4</math> subunit-containing nAChRs. SIB-1553A is also a selective neuronal nAChR ligand.</p> <p><b>Purity:</b> 99.09% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg</p>

<p><b>Simpinicline</b> (OC-02)</p> <p>Cat. No.: HY-139582</p> <p>Simpinicline (OC-02), a highly selective <b>nicotinic acetylcholine receptor (nAChR)</b> agonist, shows potent antiviral activity against the SARS-CoV-2 variants in cell culture with an <math>IC_{50}</math> of 0.04 <math>\mu</math>M.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Sofiniclin</b> (ABT 894)</p> <p>Cat. No.: HY-14824</p> <p>Sofiniclin (ABT 894), an agonist of <b>nicotinic acetylcholine receptor (nAChR)</b>, is used as a potential non-stimulant research for attention-deficit/hyperactivity disorder (ADHD).</p>  <p><b>Purity:</b> 98.54% <b>Clinical Data:</b> Phase 2 <b>Size:</b> 10 mM <math>\times</math> 1 mL, 1 mg, 5 mg, 10 mg</p>
<p><b>Spinosad</b></p> <p>Cat. No.: HY-138800</p> <p>Spinosad, a mixture of spinosyns A and D known as fermentation products of a soil actinomycete (<i>Saccharopolyspora spinosa</i>), is a biological neurotoxic insecticide with a broader action spectrum.</p>  <p><b>Purity:</b> 96.45% <b>Clinical Data:</b> Phase 4 <b>Size:</b> 100 mg, 500 mg</p>	<p><b>SR 16584</b></p> <p>Cat. No.: HY-107679</p> <p>SR 16584 is a selective antagonist of <b><math>\alpha 3\beta 4</math> nAChR</b> with an <math>IC_{50}</math> of 10.2 <math>\mu</math>M.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>SSR180711 hydrochloride</b></p> <p>Cat. No.: HY-19411</p> <p>SSR180711 hydrochloride is an orally active, selective and reversible <b><math>\alpha 7</math> acetylcholine nicotinic receptor (n-AChRs)</b> partial agonist. SSR180711 hydrochloride can act on rat <math>\alpha 7</math> n-AChR (<math>K_i=22</math> nM; <math>IC_{50}=30</math> nM) and human <math>\alpha 7</math> n-AChR (<math>K_i=14</math> nM; <math>IC_{50}=18</math> nM).</p>  <p><b>Purity:</b> 99.98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg</p>	<p><b>Sulfoxaflor</b></p> <p>Cat. No.: HY-118504</p> <p>Sulfoxaflor is a sulfoximine insecticide and is an agonist of <b>nAChR1</b> and <b>nAChR2</b> subtypes. Sulfoxaflor is used for the control of sap-feeding insects such as <i>Myzus persicae</i>, <i>Aphis gossypii</i>, <i>Bemisia tabaci</i> and <i>Nilaparvata lugens</i>.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>SUVN-911</b></p> <p>Cat. No.: HY-136146</p> <p>SUVN-911 is a potent, selective, brain penetrated and orally bioavailable neuronal nicotinic acetylcholine <b><math>\alpha 4\beta 2</math> receptor</b> antagonist, with a <math>K_i</math> of 1.5 nM. SUVN-911 has antidepressant activity.</p>  <p><b>Purity:</b> 99.67% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p><b>T761-0184</b></p> <p>Cat. No.: HY-146404</p> <p>T761-0184 is a potent <b><math>\alpha 7</math> nicotinic receptor (nAChR)</b> antagonist.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>TC-2559 difumarate</b></p> <p>Cat. No.: HY-136207</p> <p>TC-2559 difumarate is a CNS-selective, orally active <b><math>\alpha 4\beta 2</math> subtype</b> of nicotinic acetylcholine receptor (nAChR) partial agonist (<math>EC_{50}=0.18</math> <math>\mu</math>M). TC-2559 difumarate shows selectivity for <math>\alpha 4\beta 2</math> over <math>\alpha 2\beta 4</math>, <math>\alpha 4\beta 4</math> and <math>\alpha 3\beta 4</math> receptors, with <math>EC_{50}</math>s in the range of 10-30 <math>\mu</math>M. Antinociceptive effect.</p>  <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>Tebanicline dihydrochloride</b> (Ebanicline dihydrochloride; ABT-594 dihydrochloride)</p> <p>Cat. No.: HY-14316A</p> <p>Tebanicline dihydrochloride (Ebanicline dihydrochloride) is a <b>nAChR</b> modulator with potent, orally effective analgesic activity. It inhibits the binding of cytosine to <math>\alpha 4\beta 2</math> neuronal nAChRs with a <math>K_i</math> of 37 pM.</p>  <p><b>Purity:</b> 98.91% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>

<p><b>TQS</b></p> <p>Cat. No.: HY-107682</p> <p>TQS is a <math>\alpha 7</math> nicotinic acetylcholine receptor (nAChR) positive allosteric modulator. TQS can be used for the research of neuroinflammatory pain.</p>  <p><b>Purity:</b> 99.47%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p><b>Triflumezopyrim</b></p> <p>Cat. No.: HY-145296</p> <p>Triflumezopyrim, a mesoionic insecticide, has high efficiency at a low dosage, and is mainly used to control hopper species.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Tropisetron</b> (SDZ-ICS-930 free base)</p> <p>Cat. No.: HY-B0072</p> <p>Tropisetron (SDZ-ICS-930 free base) is a selective 5-HT3 receptor antagonist and <math>\alpha 7</math>-nicotinic receptor agonist with an IC50 of 70.1 <math>\pm</math> 0.9 nM for 5-HT3 receptor.</p>  <p><b>Purity:</b> <math>\geq</math>98.0%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p><b>UB-165 fumarate</b></p> <p>Cat. No.: HY-107688A</p> <p>UB-165 fumarate is a nAChR agonist, being a full agonist of the <math>\alpha 3\beta 2</math> isoform and a partial agonist of the <math>\alpha 4\beta 2^*</math> isoform, with a <math>K_i</math> value of 0.27 nM for nicotine binding in rat brain.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Varenicline</b> (CP 526555)</p> <p>Cat. No.: HY-10019</p> <p>Varenicline (CP 526555) is a potent partial agonist for <math>\alpha 4\beta 2</math> nicotinic acetylcholine receptor (nAChR) with an EC<sub>50</sub> value of 2.3 <math>\mu</math>M. Varenicline is a full agonist for <math>\alpha 3\beta 4</math> and <math>\alpha 7</math> nAChRs with EC<sub>50</sub> values of 55 <math>\mu</math>M and 18 <math>\mu</math>M, respectively.</p>  <p><b>Purity:</b> 99.70%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p><b>Varenicline Hydrochloride</b> (CP 526555 hydrochloride)</p> <p>Cat. No.: HY-10020</p> <p>Varenicline Hydrochloride (CP 526555 hydrochloride) is a high affinity, selective <math>\alpha 4\beta 2</math> nicotine acetylcholine receptor (nAChR) partial agonist and full <math>\alpha 7</math> nAChR agonist.</p>  <p><b>Purity:</b> 98.87%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p><b>Varenicline Tartrate</b> (CP 526555-18)</p> <p>Cat. No.: HY-10021</p> <p>Varenicline Tartrate (CP 526555; Champix) is a nicotinic receptor partial agonist; it stimulates nicotinic receptors more weakly than nicotine itself does.</p>  <p><b>Purity:</b> 98.03%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p><b>Varenicline-d4</b> (CP 526555-d4)</p> <p>Cat. No.: HY-10019S</p> <p>Varenicline-d4 is deuterium labeled Varenicline. Varenicline (CP 526555) is a potent partial agonist for <math>\alpha 4\beta 2</math> nicotinic acetylcholine receptor (nAChR) with an EC50 value of 2.3 <math>\mu</math>M.</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Vecuronium bromide</b> (ORG NC 45)</p> <p>Cat. No.: HY-B0118A</p> <p>Vecuronium bromide (ORG NC 45) is a neuromuscular blocking agent.</p>  <p><b>Purity:</b> <math>\geq</math>98.0%  <b>Clinical Data:</b> Launched  <b>Size:</b> 10 mM <math>\times</math> 1 mL, 50 mg, 100 mg</p>	<p><b>Xanthoplanine</b></p> <p>Cat. No.: HY-N1064</p> <p>Xanthoplanine, isolated from the root of Xylopiia parviflora, fully inhibits the EC<sub>50</sub> ACh responses of both <math>\alpha 7</math> and <math>\alpha 4\beta 2</math> nACh receptors with estimated IC<sub>50</sub> values of 9 <math>\mu</math>M (<math>\alpha 7</math>) and 5 <math>\mu</math>M (<math>\alpha 4\beta 2</math>).</p>  <p><b>Purity:</b> &gt;98%  <b>Clinical Data:</b> No Development Reported  <b>Size:</b> 5 mg, 10 mg, 25 mg</p>



<p><b>Zaldaride maleate</b> (CGS-9343B; KW 5617)</p> <p>Zaldaride maleate (CGS-9343B) is a potent, orally active and selective inhibitor of <b>calmodulin</b>. Zaldaride maleate (CGS-9343B) inhibits CaM (calmodulin)-stimulated cAMP phosphodiesterase activity, with an <math>IC_{50}</math> of 3.3 nM.</p> <p><b>Purity:</b> ≥98.0% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10 mM × 1 mL, 5 mg</p>	<p><b>Cat. No.:</b> HY-105118A</p>  <p><b>ZSET1446</b> (ST-101)</p> <p>ZSET1446 is a novel cognitive enhancer that significantly improves learning deficits in various types of Alzheimer disease (AD) models.</p> <p><b>Purity:</b> 98.07% <b>Clinical Data:</b> Phase 2 <b>Size:</b> 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg</p>  <p><b>Cat. No.:</b> HY-11013</p>
<p><b>α-Bungarotoxin</b></p> <p><b>Cat. No.:</b> HY-P1264</p> <p>α-Bungarotoxin is a competitive antagonist at <b>nicotinic acetylcholine receptors (nAChRs)</b>. α-Bungarotoxin, a selective <b>α7 receptor</b> blocker, blocks α7 currents with an <math>IC_{50}</math> of 1.6 nM and has no effects on α3β4 currents at concentrations up to 3 μM.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg</p>	<p><b>α-Conotoxin AuIB</b></p> <p><b>Cat. No.:</b> HY-P1269</p> <p>α-Conotoxin AuIB, a potent and selective <b>α3β4</b> nicotinic acetylcholine receptor (<b>nAChR</b>) antagonist, blocks α3β4 nAChRs expressed in <i>Xenopus</i> oocytes with an <math>IC_{50}</math> of 0.75 μM.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p> <p>GCCSYPPCFATNPDC-NH<sub>2</sub> (Disulfide bridge: Cys<sub>2</sub>-Cys<sub>6</sub>/Cys<sub>7</sub>-Cys<sub>13</sub>)</p>
<p><b>α-Conotoxin AuIB TFA</b></p> <p><b>Cat. No.:</b> HY-P1269A</p> <p>α-Conotoxin AuIB TFA, a potent and selective <b>α3β4</b> nicotinic acetylcholine receptor (<b>nAChR</b>) antagonist, blocks α3β4 nAChRs expressed in <i>Xenopus</i> oocytes with an <math>IC_{50}</math> of 0.75 μM.</p> <p><b>Purity:</b> 98.70% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg</p>	<p><b>α-Conotoxin MII</b> (α-CTxMII)</p> <p><b>Cat. No.:</b> HY-P1365</p> <p>α-Conotoxin MII (α-CTxMII), a 16-amino acid peptide from the venom of the marine snail <i>Conus magus</i>, potently blocks <b>nicotinic acetylcholine receptors (nAChRs)</b> composed of α3β2 subunits, with an <math>IC_{50}</math> of 0.5 nM.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p> <p>GCCSNPVCHLEHNSLNC-NH<sub>2</sub> (Disulfide bridge: Cys<sub>2</sub>-Cys<sub>6</sub>/Cys<sub>7</sub>-Cys<sub>13</sub>) (TFA salt)</p>
<p><b>α-Conotoxin MII TFA</b> (α-CTxMII TFA)</p> <p><b>Cat. No.:</b> HY-P1365A</p> <p>α-Conotoxin MII TFA (α-CTxMII TFA), a 16-amino acid peptide from the venom of the marine snail <i>Conus magus</i>, potently blocks <b>nicotinic acetylcholine receptors (nAChRs)</b> composed of α3β2 subunits, with an <math>IC_{50}</math> of 0.5 nM.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p><b>α-Conotoxin PIA</b></p> <p><b>Cat. No.:</b> HY-P1268</p> <p>α-Conotoxin PIA is a nicotinic acetylcholine receptor (<b>nAChR</b>) antagonist that targets nAChR subtypes containing α6 and α3 subunits. α-Conotoxin PIA has the potential for the research of Parkinson's disease, and schizophrenia.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p> <p>RDPCCSNPVCTVHNPQIC-NH<sub>2</sub> (Disulfide bridge: Cys<sub>4</sub>-Cys<sub>10</sub>/Cys<sub>9</sub>-Cys<sub>13</sub>)</p>
<p><b>α-Conotoxin PIA TFA</b></p> <p><b>Cat. No.:</b> HY-P1268A</p> <p>α-Conotoxin PIA TFA is a nicotinic acetylcholine receptor (<b>nAChR</b>) antagonist that targets nAChR subtypes containing α6 and α3 subunits. α-Conotoxin PIA has the potential for the research of Parkinson's disease, and schizophrenia.</p> <p><b>Purity:</b> 99.05% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg</p>	<p><b>α-Conotoxin PnIA</b></p> <p><b>Cat. No.:</b> HY-P1267</p> <p>α-Conotoxin PnIA, a potent and selective antagonist of the mammalian <b>α7 nAChR</b>, has the potential for the research of neurological conditions such as neuropathic pain and Alzheimer's disease.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p> <p>GCCSLPPCAANPDYC-NH<sub>2</sub> (Disulfide bridge: Cys<sub>2</sub>-Cys<sub>6</sub>/Cys<sub>7</sub>-Cys<sub>13</sub>)</p>

### $\alpha$ -Conotoxin PnIA TFA

Cat. No.: HY-P1267A

$\alpha$ -Conotoxin PnIA TFA, a potent and selective antagonist of the mammalian  $\alpha 7$  nAChR, has the potential for the research of neurological conditions such as neuropathic pain and Alzheimer's disease.

GCCLPPCAANNPDC-NH<sub>2</sub>  
(Disulfide bridge-Cys<sub>2</sub>-Cys<sub>3</sub>-Cys<sub>4</sub>-Cys<sub>5</sub>) (TFA salt)

**Purity:** 96.83%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### $\alpha$ -Conotoxin Vc1.1 TFA

Cat. No.: HY-125777A

$\alpha$ -Conotoxin Vc1.1 TFA is a disulfide-bonded peptide isolated from *Conus victoriae* and is a selective nAChR antagonist.


GCCLSPRCVNDHPEIC-NH<sub>2</sub>  
(Disulfide bridge-Cys<sub>2</sub>-Cys<sub>3</sub>-Cys<sub>4</sub>-Cys<sub>5</sub>) (TFA salt)

**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### $\alpha 7$ nAChR-JAK2-STAT3 agonist 1

Cat. No.: HY-146066

$\alpha 7$  nAChR-JAK2-STAT3 agonist 1 is a potent  $\alpha 7$  nAChR-JAK2-STAT3 agonist, with an IC<sub>50</sub> value of 0.32  $\mu$ M for nitric oxide (NO).  $\alpha 7$  nAChR-JAK2-STAT3 agonist 1 effectively suppresses the expression of iNOS, IL-1 $\beta$ , and IL-6 in murine RAW264.7 macrophages.



**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg